Spermicide clinicals in literature lack modern design standards.
This article was originally published in The Tan Sheet
Executive Summary
SPERMICIDE CLINICAL TRIALS SUFFER FROM LACK OF MODERN DESIGN STANDARDS, execution, analysis and reporting, Princeton University Office of Population Research Director James Trussell, PhD, told a joint meeting of four FDA advisory committees. Trussell presented a review and analysis of the existing data supporting the contraceptive efficacy of spermicides to the Reproductive Health Drugs, Nonprescription Drugs, Anti-Infective Drugs and Antiviral Drugs Advisory Committees at a Nov. 20-22 meeting in Gaithersburg, Md.
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning